Sandoz Canada launches PrSandoz® Apremilast
November 15, 2022 09:25 ET
|
Sandoz Canada
PrSandoz® Apremilast is indicated for the treatment of psoriasis plaque (PsO), psoriatic arthritis (PsA) and oral ulcers associated with Behcet’s disease.PrSandoz® Apremilast is supported by the...
Sandoz Canada poursuit l’expansion de son portfolio de produits génériques
September 21, 2022 11:12 ET
|
Sandoz Canada
Sandoz Canada a récemment mis en marché les médicaments PrSandoz® Apixaban SDZ et PrSandoz® Fesoterodine Fumarate.PrSandoz® Apixaban SDZ est un équivalent générique important; le marché de ce produit...
Sandoz Canada continues to expand its portfolio of generic products
September 21, 2022 11:12 ET
|
Sandoz Canada
Sandoz Canada recently launched PrSandoz® Apixaban SDZ and PrSandoz® Fesoterodine Fumarate. PrSandoz® Apixaban SDZ is an important generic equivalent; the market for this product has been growing for...
Sandoz Canada ajoute trois nouveaux produits à son portfolio de génériques
July 05, 2022 08:54 ET
|
Sandoz Canada
Ce printemps, les médicaments PrSandoz® Teriflunomide, PrSandoz® Lurasidone et PrSandoz® PipTaz 40,5 g ont été mis en marché au Canada.PrSandoz® Teriflunomide, le troisième médicament offert par...
Sandoz Canada expands its generics portfolio with three new products
July 05, 2022 08:54 ET
|
Sandoz Canada
PrSandoz® Teriflunomide, PrSandoz® Lurasidone, and PrSandoz® PipTaz 40.5 g all launched on the Canadian market this spring.PrSandoz® Teriflunomide, the company’s third MS treatment, is supported by...
Sandoz Canada lance PrSandoz® Dimethyl Fumarate Delayed-Release Capsules, un équivalent générique de PrTecfidera*
October 04, 2021 15:42 ET
|
Sandoz Canada
Le fumarate de diméthyle en capsules à libération retardée est indiqué comme monothérapie pour le traitement des formes rémittentes ou cycliques de la sclérose en plaques (SEP) afin de diminuer la...
Sandoz Canada launches PrSandoz® Dimethyl Fumarate Delayed-Release Capsules, a generic equivalent to PrTecfidera*
October 04, 2021 15:42 ET
|
Sandoz Canada
Dimethyl Fumarate DR Capsules is indicated as monotherapy for the treatment of relapsing remitting multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the...
Sandoz Canada lance PrSandoz® Lenalidomide, un équivalent générique de PrRevlimid®
September 03, 2021 08:47 ET
|
Sandoz Canada
PrSandoz® Lenalidomide est approuvé pour les mêmes indications que le médicament de référence PrRevlimid®.La distribution de PrSandoz® Lenalidomide se fera par l’intermédiaire du programme contrôlé de...
Sandoz Canada launches PrSandoz® Lenalidomide, a generic equivalent to PrRevlimid®
September 03, 2021 08:47 ET
|
Sandoz Canada
PrSandoz® Lenalidomide is approved for the same indications as the reference medicine PrRevlimid®.PrSandoz® Lenalidomide will be distributed through RevAid®, the same program as the reference medicine...
Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars
May 18, 2021 12:08 ET
|
Sandoz Canada
The shift announced by Quebec will follow a similar approach to policies introduced in British Columbia, Alberta and recently in New Brunswick to transition patients who use a reference biologic to a...